BAYN logo

Bayer Aktiengesellschaft Stock Price

XTRA:BAYN Community·€27.7b Market Cap
  • 3 Narratives written by author
  • 1 Comments on narratives written by author
  • 240 Fair Values set on narratives written by author

BAYN Share Price Performance

€28.20
1.43 (5.34%)
23.1% undervalued intrinsic discount
€36.67
Fair Value
€28.20
1.43 (5.34%)
27.7% undervalued intrinsic discount
€39.00
Fair Value
Price €28.20
AnalystHighTarget €39.00
AnalystConsensusTarget €28.37
AnalystLowTarget €23.00

BAYN Community Narratives

AnalystHighTarget·
Fair Value €36.67 25.2% undervalued intrinsic discount

Sustainable Farming And Rising Healthcare Will Fuel Expansion

0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AnalystConsensusTarget·
Fair Value €28.53 3.9% undervalued intrinsic discount

Crop Science And Pharmaceuticals Will Thrive On Favorable Trends

1users have liked this narrative
1users have commented on this narrative
145users have followed this narrative
AnalystLowTarget·
Fair Value €23 19.2% overvalued intrinsic discount

Crop Science And Pharmaceuticals Will Suffer Under Mounting Liabilities

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative

Recent BAYN News & Updates

Is Bayer (ETR:BAYN) A Risky Investment?

Jul 13
Is Bayer (ETR:BAYN) A Risky Investment?

Bayer Aktiengesellschaft Key Details

€46.2b

Revenue

€20.8b

Cost of Revenue

€25.4b

Gross Profit

€28.8b

Other Expenses

-€3.4b

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Nov 12, 2025
Earnings per share (EPS)
-3.48
Gross Margin
55.02%
Net Profit Margin
-7.40%
Debt/Equity Ratio
122.2%

Bayer Aktiengesellschaft Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Undervalued with moderate growth potential.

1 Risk
3 Rewards

About BAYN

Founded
1863
Employees
89556
CEO
William Anderson
WebsiteView website
www.bayer.com

Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, pain and cardiovascular risk prevention products, digestive health products, allergy products, and cold and cough products. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solutions, and pest and weed management products, as well as customer services for agriculture. It also engages in the breeding, propagation, and production/processing of seeds, including seed dressing. The company distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.

Market Insight

Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading

German Market Performance

  • 7 Days: 0.5%
  • 3 Months: -0.1%
  • 1 Year: 14.9%
  • Year to Date: 13.8%
The market is up 1.5% over the last week, with the Industrials sector leading the way, up 2.7%. In the last year, the market has climbed 15%. As for the next few years, earnings are expected to grow by 17% per annum. Market details ›